Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Age Related Macular Degeneration
Company announces positive interim EVIZON phase II AMD data
June 17th, 2005
Genaera Corp. (GENR) and study investigators announced positive interim clinical trial results, including safety data and visual acuity outcomes, from a multicenter, randomized, masked, U.S., phase II clinical trial (MSI-1256F-208). The study is one of a continuing series evaluating EVIZON (squalamine lactate) for the treatment of choroidal neovascularization associated with age-related macular degeneration (AMD), also known as "wet" AMD. Data was presented on May 3, 2005 at the Association for Research in Vision and Ophthalmology annual meeting by retinal specialist and study investigator, Thomas A. Ciulla, MD, Midwest Eye Institute, Indianapolis, Indiana. ...
Source: Drug Week (2005-06-17)
|
